Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzastaurin plus paclitaxel/carboplatin followed by maintenance enzastaurin in first-line advanced ovarian cancer
2006-002316-10Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of enzastaurin in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Progression-free survival. Started Aug 2006; status: completed.
02
Drugs
enzastaurin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2006-002316-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002316-10.